Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) Director Behzad Aghazadeh bought 2,383,333 shares of the firm’s stock in a transaction on Friday, July 24th. The stock was bought at an average price of $15.15 per share, with a total value of $36,107,494.95. Following the completion of the purchase, the director owned 3,080,983 shares of the company’s stock, valued at $46,676,892.45. This trade represents a 341.62% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Behzad Aghazadeh also recently made the following trade(s):
- On Tuesday, July 28th, Behzad Aghazadeh bought 7,905 shares of Scribe Therapeutics stock. The stock was bought at an average cost of $18.25 per share, for a total transaction of $144,266.25.
Scribe Therapeutics Stock Performance
Scribe Therapeutics stock opened at $18.36 on Thursday. Scribe Therapeutics Inc. has a one year low of $17.31 and a one year high of $25.49.
Recommended Stories
- Five stocks we like better than Scribe Therapeutics
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
